Deal Tracker · Countries

United Kingdom pharma deals

11 pharma deals involving United Kingdom — companies based there or deals covering the market — tracked by EPT: distribution, licensing & investment. Most active: Accord Healthcare, AstraZeneca, Hikma Pharmaceuticals & Rem3dy Health. Latest: Hikma Ventures → Rem3dy Health (Equity / Investment, 11 Nov 2026).

11
deals tracked
10
announced in 2026
$220m
disclosed value (1 deal)
27%
distribution, the top deal type
  • EPT has tracked 11 United Kingdom pharma deals (2025–2026), 10 of them announced in 2026.
  • The most common structures are distribution (27%), licensing (27%) & investment (9%).
  • Values were disclosed for 1 of 11 deals, totalling $220m; the largest is Ennogen Healthcare → Aspen Pharmacare ($220m, 2 Nov 2026).
  • The most active companies: Accord Healthcare (2), AstraZeneca (2), Hikma Pharmaceuticals (2) & Rem3dy Health (2).

Most active companies

Accord Healthcare (2) · AstraZeneca (2) · Hikma Pharmaceuticals (2) · Rem3dy Health (2)

Countries involved

UAE (5) · Saudi Arabia (3) · Argentina (1) · Bahrain (1) · Brazil (1) · Canada (1)

Largest disclosed deals

Questions

How many United Kingdom pharma deals has EPT tracked?
11 as of 11 Nov 2026, covering 2025–2026; 10 were announced in 2026. The most recent is Hikma Ventures → Rem3dy Health (Equity / Investment, 11 Nov 2026).
What types of United Kingdom pharma deals are most common?
Distribution: 3 (27%); Licensing: 3 (27%); Equity / Investment: 1 (9%); M&A / Acquisition: 1 (9%).
Which companies are most active in United Kingdom pharma deals?
Accord Healthcare (2 deals), AstraZeneca (2 deals), Hikma Pharmaceuticals (2 deals), Rem3dy Health (2 deals).
What is the largest disclosed United Kingdom pharma deal?
Ennogen Healthcare → Aspen Pharmacare: $220m (M&A / Acquisition, 2 Nov 2026). Values are as announced by the parties.

Browse deals

By region

GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)

By country

Saudi Arabia (69) · UAE (61) · China (31) · Egypt (27) · United States (26) · Oman (20) · India (19) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)

By year

2026 (193) · 2025 (27) · 2024 (6) · 2022 (3) · 2021 (2)

By therapeutic area

Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)